

Synthesis of New Pyrrolidine C-Nucleosides via Staudinger-aza-Wittig Cyclization of γ -Azido Ketone

Dong Chan Kim,^{1,2} Kyung Ho Yoo,¹ Dong Jin Kim,¹ Bong Young Chung,^{2*}
and Sang Woo Park,^{1*}

¹Medicinal Chemistry Research Center, Korea Institute of Science and Technology, Seoul 130-650, Korea

²Department of Chemistry, Korea University, Seoul 136-701, Korea


Received 25 March 1999; revised 16 April 1999; accepted 23 April 1999

Abstract: Novel *N*-acetyl *C*-aza-2-deoxy-D-ribonucleosides were synthesized from 2-deoxy-D-ribose via a consecutive procedure of the addition of ortho-lithiated pyrimidine salt, Staudinger-aza-Wittig ring cyclization, and reduction of cyclic imine. © 1999 Elsevier Science Ltd. All rights reserved.

Keywords: Pyrrolidine *C*-nucleosides; Staudinger-aza-Wittig cyclization; γ -Azido ketone

During last decade structurally modified nucleosides have drawn a great deal of attention due to their potential as cancer and viral chemotherapy, and antisense oligonucleotides¹. Especially, the nucleosides with modified sugar, in which the furanose ring is replaced by a different 5-membered heterocycle containing sulfur or nitrogen atom, have proved to be potent antiviral agents.²

Our interest is the development of novel bioactive and structurally modified *C*-aza-furanose nucleoside analogs, in which the pyrrolidinyl moiety is linked to pyrimidine base with a carbon-carbon glycosidic bond. We now wish to describe our results on the efficient synthesis of both α - and β -anomers of new class of *C*-azafuranose nucleosides **1** using Staudinger-aza-Wittig cyclization of γ -azido ketone **2** which is derived from 2-deoxy-D-ribose as a starting material (Scheme 1).




Scheme 1. Retrosynthesis of Pyrrolidine C-Nucleoside

Although several methods for the synthesis of *N*-azanucleosides³⁻⁷ have been studied, only


a few examples for *C*-azanucleosides⁸⁻¹² have been known. Recently, Yokoyama and coworkers reported the preparation of 4'-epimers of *C*-azanucleosides with various hetero-aromatic compounds using reductive aminocyclization of 1,4-diketones.¹³

Azido group has very useful functionality for the synthesis of various types of nitrogen-bearing heterocycles. The ready preparation of iminophosphoranes from azides by Staudinger reaction,¹⁴ and their utilities for the formation of cyclic imines *via* intramolecular aza-Wittig type ring cyclization reactions were well known.¹⁵ Based on these facts, Staudinger-aza-Wittig method was applied for the synthesis of *C*-azanucleosides in this work. The azide group with (*R*)-configuration at C-4 in **2** was introduced by a stepwise double inversion from 2-deoxy-D-ribose (**3**) using Mitsunobu method. And cyclic imine **13**, retaining configuration of the furanose ring at C-3 and C-4, was obtained by intramolecular ring cyclization under mild and neutral reaction conditions in excellent yield.



Scheme 2. Reagents and reaction conditions: (i) MeOH, HCl, Ag₂CO₃, 0°C (92%); (ii) BnBr, THF, NaH, TBAI, rt (87%); (iii) a. AcOH, H₂O, 100°C, b. NaBH₄, EtOH, 0°C (65%); (iv) TrCl, DMAP, DCM, Et₃N, rt (98%); (v) Ph₃P, DEAD, 4-nitrobenzoic acid, benzene, 0°C, 5h (93%); (vi) K₂CO₃, MeOH, rt, 3h (95%); (vii) 4-methoxybenzyl chloride, NaH, DMF, 0°C (92%); (viii) 4-CH₃C₆H₄SO₃H, DCM, MeOH, rt (98%); (ix) (COCl)₂, DMSO, Et₃N, DCM, -78°C (98%)


Etherification of the anomeric hydroxyl group of 2-deoxy-D-ribose (**3**) followed by treatment with benzyl bromide gave methyl 3,5-di-*O*-benzyl-2-deoxy-D-ribofuranoside (**4**) as depicted in Scheme 2. After hydrolysis with 80% aqueous acetic acid, the resulting aldehyde was reduced by NaBH₄ to afford the diol **5**. The (*R*)-configuration of secondary hydroxyl group at C-4 was inverted to (*S*)-configuration by Mitsunobu method to give **6**. The C-4 hydroxyl group of **6** was protected with 4-methoxybenzyl chloride. The selective deprotection of the trityl group afforded the primary alcohol **7**, which was then converted into the aldehyde **8** by



Scheme 3. Reagents and reaction conditions: (i) THF, -78°C (48%); (ii) Ac₂O, pyridine, DMAP, rt (93%); (iii) DDQ, DCM, H₂O, rt (84%); (iv) Ph₃P, DEAD, DPPA, THF, rt (91%); (v) K₂CO₃, MeOH, rt (98%); (vi) MnO₂, THF, 24h (81%); (vii) Ph₃P, THF, rt (91%)

Swern oxidation. Overall yield of **8** from **3** was about 40%.

The aldehyde **8** was served as a precursor for the synthesis of key intermediate, γ -azido ketone **2** as shown in Scheme 3. Condensation of the aldehyde **8** with ortho-lithiated 2,4-di-*O*-benzylpyrimidine **9**¹⁶, which was prepared from lithium 2,2,6,6-tetramethylpiperidine and 2,4-di-*O*-benzylpyrimidine in THF at -78 °C, provided a 3:1 diastereomeric mixture of **10** in 48% yield. Protection of hydroxyl group at C-1 by acetic anhydride with the stereoisomeric mixture, and subsequent oxidative removal of 4'-methoxybenzyl group at C-4 by 2,3-dichloro-5,6-dicyanobenzoquinone¹⁷ produced the secondary alcohol **11**. **11** was then treated with diphenylphosphoryl azide¹⁸ by Mitsunobu method to give azide **12** with inversion of configuration at C-4. Base-catalyzed hydrolysis of **12** and subsequent oxidation of the resulting secondary alcohol by manganese(IV) oxide afforded γ -azido ketone[†] **2**. The cyclized imine **13** was prepared from **2** using triphenylphosphine in THF at room temperature for 18 hours *via* Staudinger-aza-Wittig ring cyclization in 91% yield.



Scheme 4. Reagents and reaction conditions: (i) NaBH_3CN , MeOH, *cat.* AcOH (**14a**:41%,**14b**:38%); (ii) Ac_2O , pyridine, *cat.* DMAP (**15a**:92%,**15b**:91%); (iii) 10% Pd/C, H_2 , MeOH (**1a**:89%,**1b**:85%)

Reduction of the imine group in **13** was successfully accomplished with sodium cyanoborohydride in methanol at room temperature to afford a *ca.* 1:1 mixture of β - and α -anomers[‡] **14a** and **14b**, which could be separated by preparative TLC using $\text{CHCl}_3/\text{MeOH}$ (98:2) in 41% and 38% isolated yields, respectively. The anomeric configurations of the two epimers were confirmed by NOE experiments.^{||} Acetylation of **14a** and **14b** followed by

[†] Data for selected products are as follows. **2**: $^1\text{H-NMR}$ (300MHz, CDCl_3) δ 8.83 (s, 1H, pyrimidine H-6), 7.51-7.16 (m, 20H, 4Ar), 5.52-5.43 (m, 4H, 2 CH_2Ar), 4.59-4.39 (m, 4H, 2 CH_2Ar), 4.26 (ddd, 1H, $J_1=8.0\text{Hz}$, $J_2=3.7\text{Hz}$, $J_3=4.4\text{Hz}$, H-3'), 3.71-3.69 (m, 1H, H-4'), 3.58-3.45 (m, 2H, H-5'), 3.31 (dd, 1H, $J_1=17.8\text{Hz}$, $J_2=8.0\text{Hz}$, H-2' $_{\alpha}$), 3.07 (dd, 1H, $J_1=17.8\text{Hz}$, $J_2=3.7\text{Hz}$, H-2' $_{\beta}$).

[‡] **14a**: $^1\text{H-NMR}$ (300MHz, CDCl_3) δ 8.34 (s, 1H, pyrimidine H-6), 7.49-7.21 (m, 20H, 4Ar), 5.41 (s, 2H, CH_2Ar), 5.39 (s, 2H, CH_2Ar), 4.55-4.45 (m, 5H, H-1', 2 CH_2Ar), 3.97-3.92 (m, 1H, H-3'), 3.52-3.41 (m, 3H, H-4', H-5'), 2.30 (ddd, 1H, $J_1=13.1\text{Hz}$, $J_2=6.2\text{Hz}$, $J_3=1.4\text{Hz}$, H-2' $_{\alpha}$), 2.06-1.96 (bs, 1H, NH), 1.76 (ddd, 1H, $J_1=13.1\text{Hz}$, $J_2=10.3\text{Hz}$, $J_3=6.3\text{Hz}$, H-2' $_{\beta}$); **14b**: $^1\text{H-NMR}$ (300MHz, CDCl_3) δ 8.42 (s, 1H, pyrimidine H-6), 7.49-7.21 (m, 20H, 4Ar), 5.41 (d, 2H, $J=2.4\text{Hz}$, CH_2Ar), 5.40 (s, 2H, CH_2Ar), 4.52-4.45 (m, 4H, 2 CH_2Ar), 4.42 (dd, 1H, $J_1=7.6\text{Hz}$, $J_2=7.2\text{Hz}$, H-1'), 4.02-3.94 (m, 1H, H-3'), 3.60-3.45 (m, 3H, H-4', H-5'), 2.50 (ddd, 1H, $J_1=13.0\text{Hz}$, $J_2=7.2\text{Hz}$, $J_3=6.7\text{Hz}$, H-2' $_{\beta}$), 2.39-2.21 (bs, 1H, NH), 1.88 (ddd, 1H, $J_1=13.0\text{Hz}$, $J_2=7.6\text{Hz}$, $J_3=6.3\text{Hz}$, H-2' $_{\alpha}$).

^{||} The C-1 configurations of **14a** and **14b** were assigned by NOE experiments. At first, the irradiation of H_3 at C-3 in **14a** and **14b** led to a 1.4% and 1.7% increase in the intensity of signal for $\text{H}_{2\beta}$ at C-2, respectively. Secondly, in the case of **14a** the irradiation of $\text{H}_{2\alpha}$ at C-2 led to a 3.5% increase in the intensity of signal for H_1 and that of $\text{H}_{2\beta}$ at C-2 led to a 2.2% increase for H_3 . However, in **14b**,

hydrogenolysis over 10% Pd-C provided the corresponding *N*-acetyl-5(*R*)-hydroxymethyl-4(*S*)-hydroxy-2(*R*)- and 2(*S*)-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)pyrrolidine[†], **1a** and **1b** (Scheme 4).

In conclusion, an efficient method for the synthesis of new pyrrolidine *C*-nucleoside *via* Staudinger-aza-Wittig cyclization of γ -azido ketone has been developed. This research provides the possibility for the synthesis of other aza *C*-nucleosides using several sugars and lithium salts of heteroaromatic compounds. The biological evaluations and preparation for oligonucleotides using **1** are in progress.

Acknowledgment: We thank the Il-Dong Pharm. Co. for its donation of Chair Fund to KIST.

References

- For recent reviews see: a) Goodchild, J. *Bioconjugate Chem.* **1990**, 1, 165-187. b) Uhlmann, E.; Peyman, A. *Chem. Rev.* **1990**, 90, 543-584. c) Milligan, J. F.; Matteucci, M. D.; Martin, J. C. *J. Med. Chem.* **1993**, 36, 1923-1937. d) Thuong, N. T.; Helene, C. *Angew. Chem. Int. Ed. Engl.* **1993**, 32, 666-690. e) Kool, E. T. *Chem. Rev.* **1997**, 97, 1473-1487.
- a) Secrist III, J. A.; Tiwari, K. N.; Riordan, J. M.; Montgomery, J. A. *J. Med. Chem.* **1991**, 34, 2361-2366. b) Chu, C. K.; Beach, J. W.; Jeong, L. S.; Choi, B. G.; Comer, F. I.; Alves, A. J.; Schinazi, R. F. *J. Org. Chem.* **1991**, 56, 6503-6505. c) Ng, K. E.; Orgel, L. E. *J. Med. Chem.* **1989**, 32, 1754-1757. d) Peterson, M. L.; Vince, R. *J. Med. Chem.* **1991**, 34, 2787-2797.
- Huang, B.; Chen, B.; Hui, Y. *Synthesis* **1993**, 769-771.
- Altmann, K. H. *Tetrahedron Lett.* **1993**, 34, 7721-7724.
- Altmann, K. H.; Freier, S. M.; Piels, U.; Winkler, T. *Angew. Chem. Int. Ed. Engl.* **1994**, 33, 1654-1657.
- Rassu, G.; Pinna, L.; Spanu, P.; Ulgheri, F.; Casiraghi, G. *Tetrahedron Lett.* **1994**, 35, 4019-4022.
- Pickering, L.; Malhi, B. S.; Coe, P. L.; Walker, R. T. *Tetrahedron* **1995**, 51, 2719-2728.
- Just, G.; Donnini, G. P. *Can. J. Chem.* **1977**, 55, 2998-3006.
- Kini, G. D.; Hennen, W. J.; Robins, R. K. *J. Org. Chem.* **1986**, 51, 4436-4439.
- Horenstein, B. A.; Zabinski, R. F.; Schramm, V. L. *Tetrahedron Lett.* **1993**, 34, 7213-7216.
- a) Yokoyama, M.; Akiba, T.; Ochiai, Y.; Momotake, A.; Togo, H. *J. Org. Chem.* **1996**, 61, 6079-6082. b) Momotake, A.; Mito, J.; Yamaguchi, K.; Togo, H.; Yokoyama, M. *J. Org. Chem.* **1998**, 63, 7207-7212.
- Furneaux, R. H.; Limberg, G.; Tyler, P. C.; Schramm, V. L. *Tetrahedron* **1997**, 53, 2915-2930.
- Yokoyama, M.; Ikeue, T.; Ochiai, Y.; Momotake, A.; Yamaguchi, K.; Togo, H. *J. Chem. Soc., Perkin Trans 1.* **1998**, 2185-2191.
- Gololobov, Y. G.; Zhmurova, I. N.; Kasukhin, L. F. *Tetrahedron* **1981**, 37, 437-472.
- a) Lambert, P. H.; Vaultier, M.; Carrie, R. *J. Chem. Soc., Chem. Commun.* **1982**, 1224-1225. b) Lambert, P. H.; Vaultier, M.; Carrie, R. *J. Org. Chem.* **1985**, 50, 5352-5356. c) Molina, P.; Vilaplana, M. J. *Synthesis* **1994**, 1197-1218.
- Mattson, R. J.; Sloan, C. P. *J. Org. Chem.* **1990**, 55, 3410-3412.
- Oikawa, Y.; Yoshioka, T.; Yonemitsu, O. *Tetrahedron Lett.* **1982**, 23, 885-888.
- Lal, B.; Pramanik, B. N.; Manhas, M. S.; Bose, A. K. *Tetrahedron Lett.* **1977**, 1977-1980.

only when H₂ at C-2 was irradiated, increases (5.4% and 2.4%) in the intensity of signals for H₁ and H₃ were observed. Accordingly, it is concluded that the configuration at C-1 of **1a** is β -anomer and that of **1b** is α -anomer.

[†] **1a**: ¹H-NMR (300MHz, D₂O) δ 7.43 (s, 0.38H, pyrimidine H-6, rotamer), 7.15 (s, 0.62H, pyrimidine H-6, rotamer), 4.94-4.74 (m, 1H, H-1'), 4.31-4.21 (m, 1H, H-3'), 4.03-3.90 (m, 1H, H-4'), 3.70-3.50 (m, 2H, H-5'), 2.42-2.25 (m, 1H, H-2'_α), 2.16-1.91 (m, 2.82H, H-2'_β, CH₃CO, rotamer), 1.87 (s, 1.18H, CH₃CO, rotamer); HRMS (FAB, NBA) [Found (M+H), 270.1089. Cal. for C₁₁H₁₆N₂O₅: (M+H)⁺ *m/z*, 270.1090]; **1b**: ¹H-NMR (300MHz, CD₃OD) δ 7.18 (s, 0.64H, pyrimidine H-6, rotamer), 7.09 (s, 0.36H, pyrimidine H-6, rotamer), 4.94-4.79 (m, 1H, H-1'), 4.29-4.24 (m, 1H, H-3'), 4.09-4.03 (m, 0.60H, H-4', rotamer), 3.97-3.90 (m, 0.60H, H-4', rotamer), 3.68-3.38 (m, 2H, H-5'), 2.58-2.44 (m, 1H, H-2'_β), 2.08 (s, 1.24H, CH₃CO, rotamer), 1.88-1.70 (m, 2.76H, H-2'_α, CH₃CO, rotamer); HRMS (FAB, NBA) [Found (M + H), 270.1091. Cal. for C₁₁H₁₆N₂O₅: (M+H)⁺ *m/z*, 270.1090].